Glenmede Trust Co. NA Acquires 679 Shares of Azenta, Inc. (NASDAQ:AZTA)

Glenmede Trust Co. NA increased its holdings in shares of Azenta, Inc. (NASDAQ:AZTA) by 6.3% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 11,379 shares of the company’s stock after acquiring an additional 679 shares during the period. Glenmede Trust Co. NA’s holdings in Azenta were worth $551,000 at the end of the most recent reporting period.

Other hedge funds have also bought and sold shares of the company. Hantz Financial Services Inc. bought a new stake in Azenta during the second quarter worth about $30,000. Farther Finance Advisors LLC boosted its stake in Azenta by 20.0% during the third quarter. Farther Finance Advisors LLC now owns 1,537 shares of the company’s stock worth $74,000 after acquiring an additional 256 shares in the last quarter. Benjamin F. Edwards & Company Inc. boosted its stake in Azenta by 150.9% during the second quarter. Benjamin F. Edwards & Company Inc. now owns 1,588 shares of the company’s stock worth $84,000 after acquiring an additional 955 shares in the last quarter. Net Worth Advisory Group bought a new stake in Azenta during the third quarter worth about $205,000. Finally, Aigen Investment Management LP bought a new stake in Azenta during the third quarter worth about $214,000. Institutional investors own 99.08% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have issued reports on the stock. Evercore ISI decreased their target price on shares of Azenta from $53.00 to $50.00 and set an “in-line” rating for the company in a report on Tuesday, October 1st. Needham & Company LLC decreased their target price on shares of Azenta from $69.00 to $55.00 and set a “buy” rating for the company in a report on Wednesday, November 13th. Three equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. According to MarketBeat.com, Azenta has a consensus rating of “Hold” and an average price target of $63.60.

Insider Activity

In other Azenta news, CFO Herman Cueto sold 712 shares of the company’s stock in a transaction that occurred on Tuesday, November 19th. The shares were sold at an average price of $40.07, for a total transaction of $28,529.84. Following the completion of the sale, the chief financial officer now directly owns 23,892 shares of the company’s stock, valued at approximately $957,352.44. This represents a 2.89 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director William L. Cornog bought 12,500 shares of Azenta stock in a transaction on Monday, November 18th. The shares were acquired at an average cost of $39.60 per share, with a total value of $495,000.00. Following the completion of the acquisition, the director now owns 14,755 shares of the company’s stock, valued at $584,298. The trade was a 554.32 % increase in their position. The disclosure for this purchase can be found here. Insiders sold 3,018 shares of company stock valued at $126,689 over the last three months. Insiders own 1.77% of the company’s stock.

Azenta Price Performance

AZTA opened at $46.97 on Wednesday. The firm has a 50 day moving average price of $44.91 and a 200-day moving average price of $49.84. Azenta, Inc. has a twelve month low of $38.82 and a twelve month high of $69.16.

Azenta (NASDAQ:AZTA) last released its quarterly earnings data on Tuesday, November 12th. The company reported $0.18 earnings per share for the quarter, beating the consensus estimate of $0.10 by $0.08. Azenta had a negative net margin of 25.01% and a positive return on equity of 1.03%. The firm had revenue of $170.00 million during the quarter, compared to analysts’ expectations of $169.66 million. During the same period in the previous year, the company earned $0.13 earnings per share. The firm’s quarterly revenue was down 1.2% on a year-over-year basis. Equities research analysts anticipate that Azenta, Inc. will post 0.4 EPS for the current fiscal year.

Azenta Profile

Azenta, Inc provides biological and chemical compound sample exploration and management solutions for the life sciences market in North America, Africa, China, the United Kingdom, rest of Europe, the Asia Pacific, and internationally. The company operates in two reportable segments, Life Sciences Products and Life Sciences Services.